Histone Deacetylase 6: At the Interface of Cancer and Neurodegeneration

References

• Allfrey VG , FaulknerR , MirskyAE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA51(5), 786–794 (1964).
   PubMed Web of Science ®Google Scholar
• Jenuwein T , AllisCD. Translating the histone code. Science293(5532), 1074–1080 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma A , LiuH , Herwig-CarlMC , ChandDakal T , Schmidt-WolfIGH. Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers. Cancer Invest.39(3), 257–273 (2021).
   PubMed Web of Science ®Google Scholar
• Li Y , ShinD , KwonSH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J.280(3), 775–793 (2013).
   PubMed Web of Science ®Google Scholar
• Zheng YC , KangHQ , WangBet al. Curriculum vitae of HDAC6 in solid tumors. Int. J. Biol. Macromol.230, 123219 (2023).
   PubMed Web of Science ®Google Scholar
• Li T , ZhangC , HassanSet al. Histone deacetylase 6 in cancer. J. Hematol. Oncol.11(1), 111 (2018).
   PubMed Web of Science ®Google Scholar
• LoPresti P . HDAC6 in diseases of cognition and of neurons. Cells10(1), (2020).
   PubMed Web of Science ®Google Scholar
• Shen S , KozikowskiAP. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019). Expert Opin. Ther. Pat.30(2), 121–136 (2020).
   PubMed Web of Science ®Google Scholar
• Pulya S , AminSA , AdhikariN , BiswasS , JhaT , GhoshB. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol. Res.163, 105274 (2021).
   PubMed Web of Science ®Google Scholar
• Pu J , LiuT , SharmaA , Schmidt-WolfIGH. Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment. BMC Med. Genomics16(1), 295 (2023).
   PubMed Web of Science ®Google Scholar
• Aldana-Masangkay GI , SakamotoKM. The role of HDAC6 in cancer. J. Biomed. Biotechnol.2011, 875824 (2011).
   PubMed Web of Science ®Google Scholar
• Marquard L , GjerdrumLM , ChristensenIJ , JensenPB , SehestedM , RalfkiaerE. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology53(3), 267–277 (2008).
   PubMed Web of Science ®Google Scholar
• Van Damme M , CrompotE , MeulemanNet al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics7(12), 1403–1412 (2012).
   PubMed Web of Science ®Google Scholar
• Lin XJ , CaiLM , QianZJet al. Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma. Onco. Targets Ther.10, 5129–5136 (2017).
   PubMed Web of Science ®Google Scholar
• Li C , CaoL , XuCet al. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. Hum. Pathol.75, 16–25 (2018).
   PubMed Web of Science ®Google Scholar
• Saji S , KawakamiM , HayashiSet al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene24(28), 4531–4539 (2005).
   PubMed Web of Science ®Google Scholar
• Haakenson J , ZhangX. HDAC6 and ovarian cancer. Int. J. Mol. Sci.14(5), 9514–9535 (2013).
   PubMed Web of Science ®Google Scholar
• Yano M , MiyazawaM , OganeNet al. Up-regulation of HDAC6 results in poor prognosis and chemoresistance in patients with advanced ovarian high-grade serous carcinoma. Anticancer Res.41(3), 1647–1654 (2021).
   PubMed Web of Science ®Google Scholar
• Yano M , KatohT , MiyazawaMet al. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Sci. Rep.9(1), 2397 (2019).
   PubMedGoogle Scholar
• Hou H , ZhaoL , ChenWet al. Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma. Int. J. Exp. Pathol.96(4), 248–254 (2015).
   PubMed Web of Science ®Google Scholar
• Cosenza M , CivalleroM , MarcheselliL , SacchiS , PozziS. Citarinostat and momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis25(5–6), 370–387 (2020).
   PubMed Web of Science ®Google Scholar
• Keremu A , AimaitiA , LiangZ , ZouX. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother. Pharmacol.83(2), 255–264 (2019).
   PubMed Web of Science ®Google Scholar
• M L , PPV , TKet al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol.10(5), 735–750 (2016).
   PubMed Web of Science ®Google Scholar
• Simoes-Pires C , ZwickV , NurissoA , SchenkerE , CarruptPA , CuendetM. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Mol. Neurodegener.8, 7 (2013).
   PubMed Web of Science ®Google Scholar
• Trzeciakiewicz H , AjitD , TsengJHet al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun.11(1), 5522 (2020).
   PubMed Web of Science ®Google Scholar
• Tseng CC , HuangSY , TsaiHP , WuCW , HsiehTH. HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma. Sci. Rep.12(1), 10513 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang Z , CaoY , ZhaoW , GuoL , LiuW. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark.19(2), 169–175 (2017).
   PubMed Web of Science ®Google Scholar
• Hu Z , RongY , LiS , QuS , HuangS. Upregulated histone deacetylase 6 associates with malignant progression of melanoma and predicts the prognosis of patients. Cancer Manag. Res.12, 12993–13001 (2020).
   PubMed Web of Science ®Google Scholar
• Xie X , LuoK , LiYet al. Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer. Cancer Manag. Res.10, 5451–5460 (2018).
   PubMed Web of Science ®Google Scholar
• Zou S , TongQ , LiuB , HuangW , TianY , FuX. Targeting STAT3 in cancer immunotherapy. Mol. Cancer19(1), 145 (2020).
   PubMed Web of Science ®Google Scholar
• Kuo IY , YangYE , YangPSet al. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics11(14), 7029–7044 (2021).
   PubMed Web of Science ®Google Scholar
• Shen M , XuZ , XuWet al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J. Exp. Clin. Cancer Res.38(1), 149 (2019).
   PubMedGoogle Scholar
• Herrmann A , LahtzC , NagaoTet al. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res.77(18), 5118–5128 (2017).
   PubMed Web of Science ®Google Scholar
• Ou L , WangH , HuangHet al. Preclinical platforms to study therapeutic efficacy of human gammadelta T cells. Clin. Transl. Med.12(6), e814 (2022).
   PubMed Web of Science ®Google Scholar
• Stephan D , WeiherH , Schmidt-WolfIGH. CIK cells and HDAC inhibitors in multiple myeloma. Int. J. Mol. Sci.18(5), (2017).
   Web of Science ®Google Scholar
• Sharma A , Schmidt-WolfIGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J. Exp. Clin. Cancer Res.40(1), 388 (2021).
   PubMed Web of Science ®Google Scholar
• Auzmendi-Iriarte J , Saenz-AntonanzasA , Mikelez-AlonsoIet al. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis.11(6), 417 (2020).
   PubMed Web of Science ®Google Scholar
• Han MH , KimJM , CheongJHet al. Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Front. Oncol.12, 851628 (2022).
   PubMed Web of Science ®Google Scholar
• Kong DS , NamDH , KangSHet al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget8(4), 7003–7013 (2017).
   PubMed Web of Science ®Google Scholar
• Sharma A , WullnerU , Schmidt-WolfIGH , MaciaczykJ. Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration. Front. Mol. Neurosci.16, 1155177 (2023).
   PubMed Web of Science ®Google Scholar
• Sharma A , LiuH , Tobar-TosseFet al. Ubiquitin carboxyl-terminal hydrolases (UCHs): potential mediators for cancer and neurodegeneration. Int. J. Mol. Sci.21(11), (2020).
   Web of Science ®Google Scholar
• Rodrigues DA , PinheiroPSM , SagrilloFS , BolognesiML , FragaCAM. Histone deacetylases as targets for the treatment of neurodegenerative disorders: challenges and future opportunities. Med. Res. Rev.40(6), 2177–2211 (2020).
   PubMed Web of Science ®Google Scholar
• Lemos M , StefanovaN. Histone deacetylase 6 and the disease mechanisms of alpha-synucleinopathies. Front. Synaptic. Neurosci.12, 586453 (2020).
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y , KovacsJJ , McLaurinA , VanceJM , ItoA , YaoTP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell115(6), 727–738 (2003).
   PubMed Web of Science ®Google Scholar
• Mazzocchi M , CollinsLM , SullivanAM , O’KeeffeGW. The class II histone deacetylases as therapeutic targets for Parkinson’s disease. Neuronal Signal.4(2), NS20200001 (2020).
   PubMedGoogle Scholar
• Ding H , DolanPJ , JohnsonGV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem.106(5), 2119–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Odagiri S , TanjiK , MoriFet al. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochem. Biophys. Res. Commun.430(1), 394–399 (2013).
   PubMed Web of Science ®Google Scholar
• Anderson KW , ChenJ , WangM , MastN , PikulevaIA , TurkoIV. Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLOS ONE10(5), e0126592 (2015).
   PubMed Web of Science ®Google Scholar
• Li E , ChoiJ , SimHRet al. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington’s disease. BMB Rep.56(2), 178–183 (2023).
   PubMedGoogle Scholar
• Bohush A , BieganowskiP , FilipekA. Hsp90 and its co-chaperones in neurodegenerative diseases. Int. J. Mol. Sci.20(20), (2019).
   PubMed Web of Science ®Google Scholar
• Gupta A , BansalA , Hashimoto-ToriiK. HSP70 and HSP90 in neurodegenerative diseases. Neurosci. Lett.716, 134678 (2020).
   PubMed Web of Science ®Google Scholar
• Depetter Y , GeursS , DeVreese Ret al. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int. J. Cancer145(3), 735–747 (2019).
   PubMed Web of Science ®Google Scholar
• Lin A , GiulianoCJ , PalladinoAet al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med.11(509), (2019).
   Web of Science ®Google Scholar
• Medard G , SheltzerJM. Ricolinostat is not a highly selective HDAC6 inhibitor. Nat. Cancer4(6), 807–808 (2023).
   PubMedGoogle Scholar